drugset / Trial / NCT06523530

Effect of a GnRH Analog on Hepatic Steatosis

NCT06523530

Non-randomizedParallel-groupOpen-labelTreatment

Summary

Menopause increases the risk of metabolic dysfunction-associated steatotic liver disease (MASLD), possibly owing to the abrupt lack of estrogen. Gonadotropin-releasing hormone (GnRH) treatment in endometriosis is regarded as a model of pharmaceutical menopause. Thus, the effect of goserelin acetate, a GnRH analog that results in transient menopause, on hepatic steatosis and fibrosis will be evaluated in this study.

Timeline

Start
2024-11-26
Primary completion
2027-04
Completion
2027-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Goserelin Other / unclassified 3.6 mg Subcutaneous

Indications